Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has announced that its New Drug Application (NDA) for the self-developed drug, Tyrosine-9591 (甲磺酸艾多替尼片), targeting brain metastases of non-small cell lung cancer (NSCLC), has been officially accepted by the National Medical Products Administration (NMPA) in China, marking it as the first next-generation EGFR-TKI inhibitor for lung cancer brain metastases [1][5]. Group 1: Drug Development and Clinical Trials - The NDA submission is based on a pivotal registration clinical study (ESAONA) conducted in China, which is a multi-center, randomized, open-label, positive-controlled trial aimed at evaluating the efficacy and safety of Tyrosine-9591 compared to Osimertinib in NSCLC patients with brain metastases [3]. - The mid-term analysis of the ESAONA study, presented at the WCLC2025 conference, showed an intracranial objective response rate (iORR) of 92.8% for the Tyrosine-9591 group compared to 76.1% for the Osimertinib group, indicating a statistically significant difference [4]. - Tyrosine-9591 is designed for first-line treatment of adult patients with locally advanced or metastatic NSCLC who have EGFR exon 19 deletions or L858R mutations and central nervous system (CNS) metastases [2]. Group 2: Company Strategy and Future Outlook - The acceptance of the NDA into the priority review process by the NMPA is expected to expedite the drug's market launch, with ongoing studies on both monotherapy and combination therapy for Tyrosine-9591 [5]. - The company emphasizes its commitment to addressing unmet clinical needs and continues to explore clinical research for combination therapies to better serve patients with lung cancer brain metastases [6]. - The submission of the NDA represents a significant milestone for the company, marking its entry into the commercialization phase and reflecting its dedication to innovative drug development in the oncology field [6][8].

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has seen its stock rise nearly 5%, currently trading at 13.06 HKD, following the announcement that its investigational drug, TY-9591, has been included in the priority review list by the National Medical Products Administration (NMPA) [1] Company Summary - The investigational drug, TY-9591, is a first-class new drug intended for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 substitutions, along with central nervous system metastases [1] - The inclusion in the priority review list indicates that the review process for TY-9591 will be expedited, potentially allowing for an earlier market launch and providing new treatment options for patients in China [1] Industry Summary - The prioritization of TY-9591 reflects a growing trend in the pharmaceutical industry towards accelerating the approval processes for innovative cancer therapies, particularly those targeting specific genetic mutations [1] - This development may enhance competition in the NSCLC treatment market, as companies strive to bring effective therapies to patients more quickly [1]

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has seen its stock rise nearly 5% in the afternoon trading session, currently up 3.65% at HKD 13.06, with a trading volume of HKD 28.9062 million. The company announced that its investigational first-class new drug, TY-9591 (Axitinib), has been included in the priority review list by the National Medical Products Administration (NMPA) [1][1]. Group 1 - The drug TY-9591 is intended for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 substitution mutations, along with central nervous system metastases [1][1]. - Inclusion in the priority review list signifies an acceleration in the review process for TY-9591, potentially leading to an earlier market launch and providing new treatment options for patients in China [1][1].

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) saw its stock price increase by over 13% in early trading, currently up 8.94% at HKD 13.52, with a trading volume of HKD 40.7033 million [1] Group 1 - The company announced that its investigational first-class new drug, Tazemetostat (TY-9591), has been included in the priority review list by the National Medical Products Administration (NMPA) [1] - Tazemetostat is intended for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 substitutions, along with central nervous system metastases [1] - The inclusion in the priority review list signifies an acceleration in the review process for Tazemetostat, potentially leading to an earlier market launch and providing new treatment options for patients in China [1]

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410.HK) has received a Drug Manufacturing License from the Zhejiang Provincial Drug Administration, which is expected to positively impact the company's capacity expansion and market development in the long term [1]. Group 1: License Details - The company, Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd., is registered at 1278 Mingzhu Road, Changxing Economic Development Zone, Huzhou, Zhejiang Province [1]. - The production address is entrusted to Kailaiying Life Science Technology (Tianjin) Co., Ltd., located at No. 71, Seventh Avenue, Tianjin Economic Development Zone [1]. - The license number is Zhe20260002, valid until January 22, 2031, issued by the Zhejiang Provincial Drug Administration [1]. Group 2: Implications of the License - The acquisition of the Drug Manufacturing License is anticipated to lay the foundation for the company to commence commercial production [1]. - This development is expected to provide better treatment options for patients, addressing urgent medical needs in cancer treatment [1].